ALSO NOTED: Nastech hit on missed payment; Nastech announces Phase I data;and much more...
Free newsletter via e-mail
> Shares of Nastech Pharmaceuticals took a beating yesterday after P&G failed to make a scheduled $15 million payment in 2006. The two companies are collaborating on a nasal spray for osteoporosis. Report
> Today Nastech announced positive Phase I data on its insulin nasal spray. Release
> Solvay and Wyeth Pharmaceuticals are touting new Phase II and III data which supports the efficacy of its antipsychotic drug bifeprunox in comparison with a placebo. Report
> Tucson-based ImaRX has pulled its IPO, citing weak market conditions. Report
> Canada's ProMetic Life Sciences has pulled its IPO as well, saying that higher 2007 revenue will make the company worth more than it could expect from a public float. Report
> Migenix has raised $11.6 million in bought-deal financing. Release
And Finally... In a small number of cases, parents are using genetic screening to select embryos with defects like their own. Article
SHARE
WITH: